Prestige Consumer Healthcare Inc. (PBH) - Q1 2025 (Ended June 30, 2024) Summary
Business Context and Reporting Period
This Form 10-Q covers the first quarter of fiscal year 2025, ended June 30, 2024. Prestige Consumer Healthcare Inc. develops, manufactures, and markets over-the-counter (OTC) healthcare products in North America and international markets. The company operates through two segments: North American OTC Healthcare and International OTC Healthcare.
Key Financial Metrics
| Metric | Q1 2025 (Jun 30, 2024) | Q1 2024 (Jun 30, 2023) |
|---|---|---|
| Total Revenues | $267.1 million | $279.3 million |
| Net Income | $49.1 million | $53.3 million |
| Diluted EPS | $0.98 | $1.06 |
| Gross Margin | 54.7% | 55.4% |
| Operating Income | $72.0 million | $85.2 million |
| Operating Cash Flow | $54.8 million | $48.1 million |
| Cash & Equivalents | $34.3 million | $54.6 million (end of period) |
| Long-Term Debt (Net) | $1.09 billion | $1.13 billion (prior quarter) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 4.4% year-over-year. The North American segment declined 5.6%, driven by significant drops in Cough & Cold (-26.6%) and Women's Health (-8.1%) categories. This was partially offset by growth in Eye & Ear Care (+9.7%). The International segment grew 5.0%.
- Margin Compression: Gross margin decreased to 54.7% from 55.4%, attributed to lower revenue volumes and increased supply chain costs. Contribution margin (gross profit less marketing) fell to 39.9% from 42.4% due to higher marketing spend and margin pressure.
- Profitability: Net income decreased 7.9% to $49.1 million. Operating income declined 15.4% to $72.0 million.
- Tax Rate: The effective tax rate dropped significantly to 16.0% from 22.5%, primarily due to the release of a reserve for uncertain tax positions as statutes of limitations expired.
- Debt Reduction: The company repaid $35.0 million on its Term B-5 Loans, reducing total debt principal to $1.1 billion.
Outlook, Risks, and Management Commentary
- Supply Chain Constraints: Management highlighted ongoing shortages of ingredients and products, particularly in eye care, due to third-party manufacturer difficulties. Labor shortages and rising input costs continue to impact operations.
- Share Repurchases: The Board authorized a new $300 million share repurchase program in May 2024. During the quarter, the company repurchased approximately $26.0 million of common stock under this program, plus $5.8 million related to tax withholdings on equity awards.
- Liquidity: Cash and cash equivalents decreased by $12.2 million during the quarter, primarily due to financing activities (debt repayment and share buybacks). The company maintains $183.6 million in available borrowing capacity on its revolving credit facility.
- Risks: Key risks include dependence on third-party manufacturers (one supplier accounts for ~23% of revenue), concentration of sales (Walmart ~20%, Amazon ~13%), and potential for goodwill or intangible asset impairment if operating results decline.
Investor Verification Checklist
- Supply Chain Resolution: Verify if the reported shortages in eye care products are resolving or if they will persist into Q2, potentially further impacting revenue.
- Marketing Efficiency: Assess whether the increased advertising spend (up 8.6% YoY) will yield a return in sales growth in subsequent quarters.
- Debt Covenants: Confirm continued compliance with leverage and interest coverage ratios, especially given the high debt load relative to operating income.
- Customer Concentration: Monitor the stability of relationships with top customers (Walmart, Amazon) given their combined ~33% revenue share.
- Inventory Levels: Review inventory build-up ($152.0 million) against sales trends to ensure no significant obsolescence risks exist.